Aberrant CpG methylations play important roles in cancer development and progression. In this study, aberrant methylations in human breast cancer were searched for using methylation-sensitive representational difference analysis (MS-RDA). A CpG island (CGI) in the 5 0 region of the heparan sulfate d-glucosaminyl 3-Osulfotransferase-2 (3-OST-2) gene was found to be hypermethylated, while its exon 2 was hypomethylated. In seven breast cancer cell lines, hypermethylation of the 5 0 region and loss of 3-OST-2 expression were observed. Treatment with a demethylating agent, 5-aza-2 0 -deoxycytidine, removed the methylation of the CGI in the 5 0 region and restored its expression, demonstrating silencing of the 3-OST-2 gene. Methylation-specific PCR (MSP) analysis in 85 primary breast cancers showed that the hypermethylation of the CGI in the 5 0 region was present in 75 (88%) of them. Quantitative reverse transcriptase-PCR (RT-PCR) analysis in 37 primary breast cancers showed that the average expression level was decreased in them. Further, MSP analysis in primary colon, lung and pancreatic cancers showed that hypermethylation of the CGI in the 5 0 region was present in the colon (8/10, 80%), lung (7/10, 70%) and pancreatic (10/10, 100%) cancers. These results showed that silencing of 3-OST-2 was present in a wide range of human cancers. The 3-OST-2 gene encodes an enzyme involved in the final modification step of heparan sulfate proteoglycans (HSPGs), and its silencing is expected to result in abnormal modification of HSPGs and abnormal signal transduction. From the high incidence, silencing of the 3-OST-2 gene is expected to have high diagnostic, and potentially therapeutic, values.
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Introduction
Methylation of CpG islands (CGIs) is involved in various biological and pathological processes Feinberg, 2001) . It is physiologically involved in genomic imprinting, X-chromosome inactivation and embryonic development (Surani, 2001; Bird, 2002) . Aberrant methylations of the CGIs in the promoter regions of tumor-suppressor genes are known to cause silencing of the gene, and can work as one of the mechanisms to inactivate a gene, along with a gene mutation and loss of heterozygosity (Jones and Laird, 1999) . Inactivation by gene silencing has been reported for most tumor-suppressor genes, including p16, VHL, RB, APC and BRCA1 Clark and Melki, 2002; Jones and Baylin, 2002) .
To identify silenced genes independent of previous knowledge, we developed a genomic -scanning method for differences in DNA methylation between two genomes methylation-sensitive representational difference analysis (MS-RDA) (Ushijima et al., 1997) . A genome is digested with HpaII, a methylationsensitive restriction enzyme that recognizes 5 0 -CCGG-3 0 , and the entire restriction product is amplified by PCR. The resultant PCR product, HpaII-amplicon, is enriched with HpaII fragments that originate from hypomethylated genomic regions, and contain few repetitive sequences. When an HpaII fragment is hypomethylated in one genome but hypermethylated in the other, the fragment will be present in the HpaII-amplicon prepared from the former genome, but not in the one prepared from the latter. The presence of the DNA fragment only in the former HpaII-amplicon can be identified by a genomic subtraction technique, RDA (Lisitsyn et al., 1993) .
Here we applied the MS-RDA method to human breast cancer to isolate DNA fragments that were differentially methylated in the cancer and surrounding noncancerous tissue.
Materials and methods
Tumor samples, cell lines and DNA/RNA extraction Breast, colon, lung, and pancreatic cancer and adjacent noncancerous tissue were obtained from patients undergoing mastectomy, colectomy, pneumonectomy and pancreatectomy, respectively, with informed consents. A peripheral blood sample was obtained from a healthy volunteer with informed consent. Human mammary epithelial cells (HMECs) were purchased from Clonetics (San Diego, CA, USA). Six breast cancer cell lines, MCF-7, ZR-75-1, SK-BR-3, T-47D, MDA-MB-231 and MDA-MB-468, were purchased from American Type Culture Collection (Rockville, MD, USA), and one, YMB-1-E, was obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan). DNA was extracted by a standard phenol/chloroform procedure and ethanol precipitation (Sambrook et al., 1989) , and total RNA was isolated using ISOGEN (NIPPON GENE, Tokyo, Japan).
MS-RDA
MS-RDA was performed as described previously (Ushijima et al., 1997 ). An RHpa adaptor was ligated to 1 mg of genomic DNA that had been digested with HpaII (New England Biolabs, Beverly, MA, USA), and the ligation product was amplified by 25 cycles of PCR with RHpa24 oligonucleotide. PCR products (HpaII-amplicon) of both tester and driver were digested with MspI (New England Biolabs), a methylationinsensitive isoschizomer of HpaII, and the restricted adaptor was removed by gel-filtration chromatography. To 1 mg of the tester HpaII-amplicon, 500 pmol of a JHpa adaptor was ligated, and 200 ng of its aliquot was mixed with 40 mg of the driver HpaII-amplicon. The DNA mixture underwent heat denaturation and reannealing (competitive hybridization), and dsDNA with the JHpa adaptor on both ends was selectively amplified (selective amplification) with a JHpa24 oligonucleotide.
For the second cycle of subtraction, the JHpa adaptor was switched to a new NHpa adaptor. A total of 40 ng of the product of the first cycle was mixed with 40 mg of driver HpaIIamplicon, and competitive hybridization and selective amplification were performed. The product was cloned into the pGEM-T Easy Vector (Promega, Madison, WI, USA), and sequenced using ABI PRISM310 (PE Biosystems, Foster City, CA, USA). In all, 96 clones were analysed for independence, and clones that detected differential methylation were selected by Southern blot analysis. A CGI was defined according to a criterion by Gardiner-Garden and Frommer (1987) .
Southern blot analysis
Genomic DNAs restricted with HpaII or MspI were run in 1.0% agarose (Bio-Rad Laboratories, Hercules, CA, USA), and then capillary-transferred to a nylon filter (Hybond-N+, Amersham Pharmacia Biotech, Uppsala, Sweden). Probes were prepared using a Gene Images labeling kit (Amersham Pharmacia Biotech). Prehybridization and hybridization were carried out, and the filter was washed. Imaging was performed using a Gene Images CDP-Star detection kit (Amersham Pharmacia Biotech).
Sodium bisulfite modification and sequencing
Sodium bisulfite modification was performed according to previous reports (Clark et al., 1994; Rein et al., 1997) . Briefly, after genomic DNA was restricted with EcoRI or BamHI restriction enzyme (New England Biolabs), 500 ng of DNA was denatured in 0.6 n NaOH at 371C for 15 min. To the denatured DNA, 3.1 m NaHSO 3 (pH 5.3) and 0.5 mm hydroquinone were added, and the sample underwent 15 cycles of denaturation at 951C for 30 s and incubation at 501C for 15 min. The sample was desalted with the Wizard DNA cleanup system (Promega), and desulfonated by treatment with 0.6 n NaOH at room temperature for 5 min. The DNA sample was ethanol-precipitated with ammonium acetate, and dissolved in 20 ml of TE buffer.
By comparing the cDNA sequence (GenBank Accession number: NM 006043) of the 3-OST-2 gene against a genomic sequence, a putative transcription start site was determined at nuclectide 58 442 of the genomic sequence (AC003661). A region (from 506-bp upstream to 93-bp downstream of the transcription start site) was amplified using 2 ml of the sodiumbisulfite-treated DNA using primers, F1 (5 0 -TTTTGGGA-GGGGTAAGAGA-3 0 ) and R1 (5 0 -ACCCAAAACCCTA-TAAACCAT-3 0 ). The PCR product was cloned into pGEM-T Easy Vector, and 10 clones were sequenced using an ABI PRISM310 sequencer. Complete conversion of cytosines in non-CpG sites to thymines was confirmed.
Methylation-specific PCR
For methylation-specific PCR (MSP) (Herman et al., 1996) , 1 ml of the sodium-bisulfite-treated DNA was amplified with primers specific for hypermethylated or hypomethylated sequences. Hypermethylated DNA (from 190-bp upstream to 19-bp upstream of the putative transcription start site) was amplified using M set primers, F (5 0 -CGGTT-GTTCGGAGTTTTATC -3 0 ) and R (5 0 -GTAACGCTAC-CACGACCACG -3 0 ), and hypomethylated DNA (from 182-bp upstream to 10-bp upstream of the putative transcription start site) was amplified by U set primers, F (5 0 -TGGAGTTT-TATTGTTTAGGATT-3 0 ) and R (5 0 -AAAACTCACATAA-CACTACCACA-3 0 ). DNA from HMEC was methylated in vitro by using Sss1-methylase (New England Biolabs) and used as a control. For M set primers, an annealing temperature (581C) that did not give PCR products using DNA of HMEC was selected. PCR cycles that gave minimal bands using SssItreated DNA were observed, and four more cycles were added for actual analysis (32 cycles). For U set primers, the annealing temperature (581C) and PCR cycles (30 cycles) were similarly determined.
Quantitative RT-PCR analysis
Total RNA (3 mg) was treated with DNaseI (Life Technologies, Rockville, MD, USA) and reverse-transcribed with oligodT primer (Promega) and Superscript II reverse transcriptase (Life Technologies). Primer sequences used are as follows:
was performed using SYBR Green PCR Core Reagents (PE Biosystems) and iCycler Thermal Cycler (Bio-Rad Laboratories). The numbers of target cDNA molecules were normalized to those of GAPDH cDNA molecules.
5-Aza-2 0 -deoxycytidine treatment MDA-MB-468 cells were seeded at a density of 6 Â 10 5 cells/ 10 cm plate on day 0, and exposed to 0.5 or 1 mM 5-aza-2 0 -deoxycytidine (5-aza-dC; Sigma, St Louis, MO, USA) for 24 h on days 1 and 3. The cells were cultured in fresh media after each treatment, and harvested on day 4.
Results
Isolation of differentially methylated DNA fragments and identification of 3-OST-2 MS-RDA was performed using a sample of human breast cancer (invasive ductal carcinoma) and the surrounding noncancerous tissue. Using the cancer as the tester and the noncancerous tissue as the driver, 15 DNA fragments that were hypermethylated in the cancer were isolated (Table 1) . By MS-RDA in the opposite manner, in all, 18 DNA fragments that were hypomethylated in the cancer were isolated. These 33 DNA fragments were sequenced, and their surrounding sequences were obtained by a GenBank database search. Of the 33 fragments, 13 had a genomic region that met a criterion of a CGI (putative CGI) within 1 kb. Of the 13, 12 had genes or expressed sequence tags (ESTs) (seven known genes and five ESTs) in their vicinities.
The expression levels of these seven genes were analysed in the primary breast cancer used for MS-RDA (Figure 1) . Quantitative RT-PCR analysis revealed that the expression level of 3-OST-2 was markedly reduced in the breast cancer compared with the noncancerous counterpart. The expressions of CGI-24 protein and CLCN6 genes were moderately decreased, but those of the other four genes were not.
Silencing of 3-OST-2 in human breast cancer cell lines
The 3-OST-2 gene was selected for further analysis using seven breast cancer cell lines and HMEC because its expression was markedly reduced. By semiquantitative RT-PCR analysis, expression levels of the 3-OST-2 gene No homology n/a n/a n/a n/a EB04 AC15708 Chr. No homology n/a n/a n/a n/a EG02 No homology n/a n/a n/a n/a EG03 AL031709 Chr. No homology n/a n/a n/a n/a Ef02 AC026751 Chr.5 none No n/a Ef04
No homology n/a n/a n/a n/a Eg04 D38378 Methylation-associated silencing K Miyamoto et al were found to be lost in all the seven breast cancer cell lines (Figure 2a) . Therefore, we analysed the methylation statuses of a CGI in its 5 0 region and DNA fragment Ea09, which was located in exon 2 (Figure 2b ). The CGI in the 5 0 region was shown to be hypomethylated in HMEC, adjacent noncancerous breast tissue and blood lymphocytes, but hypermethylated in all the seven breast cancer cell lines analysed by bisulfite sequencing (representative results in Figure 2c ). Conversely, the DNA fragment Ea09 was shown to be hypermethylated in HEMC but hypomethylated in all the seven cancer cell lines by Southern blot analysis (Figure 2d ). The lost expression of the 3-OST-2 gene and the dense methylation of the CGI in the 5 0 region strongly indicated that the 3-OST-2 gene was silenced in the seven breast cancer cell lines.
To examine the role of the methylation of the CGI in the 5 0 region in the loss of expression, a breast cancer cell line, MDA-MB-468, was treated by 5-aza-dC, a demethylating agent. The methylation status of the CGI was analysed by MSP, whose specificity was confirmed (Figure 3a) . After MDA-MB-468 cells were treated with 0.5 mm of 5-aza-dC, the methylation in the 5 0 region was removed (Figure 3b ), and the 3-OST-2 expression was restored (Figure 3c ). From this, it was concluded that the 3-OST-2 gene was silenced in human breast cancer cell lines by methylation of its 5 0 region.
High incidence of 3-OST-2 silencing in primary human breast cancers
The presence of 3-OST-2 silencing was examined in primary breast cancers. By MSP, 75 of 85 primary breast cancers (88%) were shown to contain DNA molecules hypermethylated in the CGI in the 5 0 region (representative results in Figure 4a ). It was noticed that nine noncancerous samples, whose cancer samples had methylation, contained small amounts of hypermethylated DNA molecules.
Expression levels of the 3-OST-2 gene were examined in three cancers without methylation of the CGI and in 34 cancers with methylation of the CGI by the quantitative RT-PCR method. Although the expression levels in the noncancerous tissues were variable, the average level in the cancers with methylation of the CGI was significantly (Po0.005, t-test) lower than that in the noncancerous samples (Figure 4b ). It was noticed that 15 cancers with hypermethylated CGI showed almost no expression of 3-OST-2. These data indicated that silencing of the 3-OST-2 gene was present in the majority of primary human breast cancers.
Hypermethylation of 3-OST-2 in other primary human cancers
Presence of the methylation of the CGI in the 5 0 region of the 3-OST-2 gene was examined in primary human colon, lung and pancreatic cancers. MSP showed that hypermethylation was present in eight of 10 colon cancers, seven of 10 lung cancers and all of 10 pancreatic cancers ( Figure 5 ). These data indicated that 3-OST-2 silencing was also present in significant fractions of these cancers.
Discussion
Silencing of the 3-OST-2 gene was identified as the result of a search for aberrant methylations in human breast cancer by MS-RDA. The silencing was demonstrated in breast cancer cell lines, and its presence was indicated in the majority of primary breast, colon, lung and pancreatic cancers. The 3-OST-2 gene encodes an Osulfotransferase that is involved in the final modification step of glycosaminoglycan (GAG) chains of heparan sulfate proteoglycans (HSPGs) (Shworak et al., 1999; Esko and Lindahl, 2001 ), including glypicans and After bisulfite modification, a DNA fragment covering CpG sites at nucleotides À479 to nucleotides +57 was amplified, and 10 clones from each PCR sample were sequenced. Filled and open boxes show hypermethylated and hypomethylated CpG sites, respectively. All the 10 DNA molecules sequenced in MCF-7 were hypermethylated while those in HMEC were hypomethylated. (d) Hypomethylation of a putative CpG island in exon 2. Genomic DNA of HMEC and six breast cancer cell lines were digested by HpaII or MspI, and Southern blot analysis was performed with DNA fragment Ea09. DNAs from the six breast cancer cell lines were completely digested by HpaII while that of HMEC was not digested. This showed that DNAs in the breast cancer cell lines were completely hypomethylated at both ends of DNA fragment Ea09 and surrounding HpaII sites, while these sites were hypermethylated in HMEC (Stanley et al., 1999; Matsuda et al., 2001) . The final modification of GAG chains is known to be important for determining the specificity of binding of HSPGs with various proteins and for the regulatory properties of HSPGs (Bernfield et al., 1999) . HSPGs are known to play major roles in cell growth, adhesion and migration by interactions with a wide range of growth factors, morphogens, cytokines and extracellular matrices (Perrimon and Bernfield, 2000) . Silencing of the 3-OST-2 gene suggests that altered modification of HSPGs is involved in cancer development and progression in some cases. It is important to clarify how substrate specificity of HSPG is altered by lack of the modification by 3-OST-2. The very high incidence of aberrant methylation of the CGI in the 5 0 region of the 3-OST-2 gene in primary breast, colon, lung and pancreatic cancers could lead to wide diagnostic use of the aberrant methylation. In addition to analysis of DNA extracted from cancer samples, free DNA in the plasma or serum is known to be present in cancer patients (Shapiro et al., 1983; Stroun et al., 1989) . Taking advantage of the high sensitivity of MSP, aberrant methylation in the plasma or serum DNA is now being used in a variety of cancer diagnoses (Esteller et al., 1999; Silva et al., 1999; Kawakami et al., 2000) . From the high incidence of 3-OST-2 methylation in the primary cancer samples, detection of the aberrant methylation in plasma or serum DNA is expected to be useful as a tumor marker. Occasional detection of trace amounts of methylation in noncancerous samples was considered to be due to the presence of malignant or premalignant cells in the normally appearing noncancerous tissues. By a quantitative MSP method , the problem of false-positive results can be avoided (Takada et al., submitted) .
In the MS-RDA here, the 3-OST-2 gene was identified by hypomethylation of a putative CGI in its exon 2. Conversely, its 5 0 region was hypermethylated and its expression was decreased. It is known that methylation of coding sequences or introns does not block transcription (Gonzalgo et al., 1998; Jones, 1999) , but methylation changes of these regions are sometimes associated with the altered expression of genes (Jones, 1999) . In the case of the 3-OST-2 gene, it can be considered that methylation of the CGI in the 5 0 region silenced the gene, the silencing was associated with hypomethylation of a putative CGI in exon 2, and the hypomethylation in exon 2 was identified by MS-RDA. Kaneda et al., in press ). However, DNA fragments from CGIs outside promoter regions can also be isolated by MS-RDA, and some of them are associated with altered gene expression (Kaneda et al., 2002; Takai et al., 2001) . Once the role of 3-OST-2 silencing in cancer development and progression is clarified, the presence of its product in the extracellular matrix could be useful as a target for cancer therapeutics. From the high incidences of 3-OST-2 silencings in a wide range of human cancers, its diagnostic, and possibly therapeutic, values are indicated.
